Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

27.46 +1.34 (+5.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
3 Pharma Stocks That Could Make Your Grandchildren Rich
Investors might want to consider the top pharma stocks in the current environment as they are beating most others. 
Via InvestorPlace
Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
Via ACCESSWIRE
Moderna To Collaborate With Mitsubishi On Respiratory Vaccine Promotion In Japan
Moderna and Mitsubishi signed a joint agreement regarding the co-promotion of Moderna's respiratory vaccine portfolio in Japan. 
Via Benzinga
Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
Via ACCESSWIRE
Unpacking the Latest Options Trading Trends in Moderna
Via Benzinga
Unpacking the Latest Options Trading Trends in Moderna
Via Benzinga
Here's How Much $1000 Invested In Moderna 5 Years Ago Would Be Worth Today
Via Benzinga
What's Going On With Moderna Stock Friday?
Moderna's RSV vaccine, mRNA-1345, is designed to protect adults aged 60 and older from respiratory disease caused by the RSV infection. 
Via Benzinga
3 Healthcare Stocks to Sell in July Before They Crash & Burn
Many healthcare names are attractive. But drugstore chains and some drug makers have poor outlooks. Here are three healthcare stocks to sell. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
3 Biotech Stocks to Sell in July Before They Crash & Burn
While biotech stocks have potential to provide high returns, they are often overly dependent on drug approvals. Sell these before its too late 
Via InvestorPlace
3 Biotech Stocks Turning DNA Dreams Into Dollars
Investors should consider buying into one of the future avenues of medicine by investing in these three BNA biotech stocks. 
Via InvestorPlace
AI Has 'The Hallmarks Of An Inflating Bubble,' Warns Veteran Wall Street Investor
Word to the wise: Ed Yardeni, in a July 4 note, warns his clients: "Too much capital can end even the best of parties." 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
In-Depth Examination Of 10 Analyst Recommendations For Moderna
Via Benzinga
What's Going On With Moderna Stock Wednesday
Moderna announced a $176 million award for the development of an mRNA-based Influenza vaccine. 
Via Benzinga
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... 
Via Benzinga
Exposures COVID-19
London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents
Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Court, with potential appeals on the horizon and significant financial stakes... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Amid Rapidly Rising Bird Flu Cases, Moderna Lands $176M Worth US Government Contract For Vaccine
The funds will be utilized to finalize the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1 avian influenza. 
Via Benzinga
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Via ACCESSWIRE
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com, Ecopetrol, International Paper, Micron. 
Via Benzinga
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit. 
Via InvestorPlace
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Via ACCESSWIRE
Silver Prices Fell To A 6-Week Low
Silver prices held below $29 an ounce, near a six-week low, and were pressured by a strong dollar and Treasury bond yields after hawkish remarks from a Federal Reserve official. 
Via Talk Markets
Topics Bonds Economy
Exposures Debt Markets Interest Rates
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further... 
Via Benzinga
2 Stocks Down More Than 30% to Buy Right Now
These stocks have suffered as the demand for their biggest product -- the coronavirus vaccine -- waned. 
Via The Motley Fool
Exposures COVID-19
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Dow Nearly 100 Points Lower Amid Slumping Home Sales
Via Talk Markets
Topics Stocks
Exposures US Equities
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.